Children with Allergic Rhinitis and Constipation Share a Distinct Gut Signature

Up to 30% of children with allergic rhinitis also develop functional constipation, and a new multi-omics study published in June 2026 suggests this pairing is not coincidental. Researchers from Wu H, Shi L, Wang C, Liang Y, and Huang C combined shotgun metagenomic sequencing with targeted amino acid metabolomics to characterize what may be a distinct gut microbiota-metabolite-immune axis driving this dual condition, which they call ARFC. The findings are preliminary and require larger validation, but they offer the most detailed microbial portrait of ARFC in children to date.

Bacteroidota Enrichment and Bifidobacterium Depletion in ARFC Children

The most striking microbial signal in the 19 ARFC children studied, compared to 16 healthy controls matched for age, sex, and diet, was a compositional shift at the phylum level. Bacteroidota species including Bacteroides, Phocaeicola, and Parabacteroides were significantly enriched in ARFC children, while Bacillota members such as Bifidobacterium and Blautia were depleted. Beta diversity differed substantially between groups, though alpha diversity did not, suggesting the community had reorganized rather than simply shrunken. Bacteroides thetaiotaomicron, a mucin-degrading species, was positively correlated with both dust mite-specific IgE (r = 0.423) and total IgE (r = 0.545), pointing toward a possible bacterial driver of allergic sensitization. In contrast, Bifidobacterium breve showed negative correlations with dust mite-specific IgE (r = -0.316) and total IgE (r = -0.505). Prior research has documented that gut microbiota disruption is a recognized factor in pediatric functional constipation, but this study maps those disruptions alongside allergic disease in the same children for the first time.

What This Immune-Metabolic Link Means for Affected Children

Functional constipation already affects nearly 30% of children, and when it co-occurs with allergic rhinitis the clinical burden compounds. The new data suggest the immune consequences could be mechanistic rather than incidental. Among the 50 fecal metabolites that differed significantly between ARFC children and healthy controls, 44 were upregulated and 6 were downregulated. The downregulated set included several amino acids with established immunomodulatory roles: L-glutamine, which supports lymphocyte function and gut barrier integrity; GABA, a neuro-immunomodulatory metabolite produced by gut bacteria; and L-glutamic acid, L-proline, L-threonine, L-serine, L-methionine, L-alanine, and L-valine. Kynurenine and L-phenylalanine were upregulated, and Bacteroides species positively correlated with kynurenine levels, linking dysbiosis to tryptophan metabolism, a pathway known to regulate immune tolerance. KEGG pathway analysis pointed to dysregulation in mTOR and FoxO signaling, two pathways that govern T-cell fate: mTOR overactivation promotes Th2 differentiation while suppressing regulatory T cells, and FoxO dysregulation undermines Treg stability. A Th2-skewed, IgE-high immune profile is the hallmark of allergic rhinitis, so the convergence of these pathway findings with the clinical phenotype gives the proposed axis a plausible mechanistic shape.

How Metagenomics and Metabolomics Together Made the Case

The methodological core of this study was the integration of two complementary data types. Shotgun metagenomic sequencing provided comprehensive taxonomic and functional information about the gut microbiome, going beyond 16S rRNA surveys to capture species-level resolution and pathway gene content. Targeted LC-MS/MS metabolomics then quantified amino acids and their derivatives directly in fecal samples, offering a readout of what the microbial community was actually producing. Combining these streams with Spearman correlation, OPLS-DA, and KEGG enrichment analysis allowed the team to connect specific bacteria to specific metabolites to specific immune markers. Integrating metagenomics and metabolomics provides a more holistic picture of gut-host interactions than either approach alone, and the payoff here was a combined microbial-metabolic diagnostic model that achieved a cross-validated AUC of 0.946 for distinguishing ARFC from healthy controls. L-methionine and the bacterial genus Algoriella were identified as the top discriminative features in that model.

Small Sample and Cross-Sectional Design Limit What Can Be Claimed

A cross-validated AUC of 0.946 is eye-catching, but the study's limitations are substantial and the authors are explicit about them. The 35-person cohort is small and drawn from a single center, so the microbial and metabolic signatures described here may not generalize. Translating gut microbiome findings into reliable clinical tools remains difficult even with strong discovery-phase statistics, and microbiome clinical trials frequently stumble because of inter-individual variability and confounding. The cross-sectional design means the study captures associations, not causes: it cannot determine whether dysbiosis precedes ARFC, follows from it, or arises in parallel. Dietary assessment was limited to habitual patterns and may miss day-to-day variation. Rectal swab sampling may not fully represent luminal contents. Most importantly, the metabolomic panel covered only amino acids and their derivatives, omitting short-chain fatty acids and bile acids that are also likely relevant to the gut-lung axis proposed here.

Probiotics and Targeted Metabolites as Next Steps in ARFC Research

The authors frame L-methionine and Algoriella as candidate therapeutic targets, but the path from candidate to intervention requires considerably more work. Multicenter cohort studies with larger samples are the immediate need, followed by longitudinal designs that could establish the direction of causality. On the therapeutic side, probiotics show promise for improving pediatric allergic rhinitis symptoms in meta-analyses of randomized controlled trials, and the present findings add a rationale for selecting strains specifically aimed at restoring Bifidobacterium and Blautia populations. Whether restoring those taxa would simultaneously relieve constipation and reduce IgE-mediated sensitization in ARFC children remains an open and genuinely interesting question. For now, this study's contribution is descriptive: it sketches a coherent axis linking gut dysbiosis, depleted immunomodulatory amino acids, and skewed immune signaling in a population that pediatric clinicians regularly encounter but that multi-omics research has largely overlooked.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• Cross-sectional design: this study identifies associations, not causes — it cannot establish that gut microbiome changes drive allergic rhinitis or constipation.
• Very small sample (19 cases, 16 controls) from a single center; findings may not generalise to other populations.
• The machine learning model's high AUC (0.946) was validated only within this same tiny cohort using leave-one-out cross-validation — it has not been tested in an independent sample.
• Metabolomic analysis was limited to amino acids and did not measure other key microbiome outputs such as short-chain fatty acids or bile acids.
• Funding source was not disclosed by the authors.

Case-control study (19 pediatric ARFC patients, 16 healthy controls) using shotgun metagenomics and targeted amino acid metabolomics. The cross-sectional design establishes associations only and cannot determine causal direction. The machine learning model's discriminative performance was assessed solely within this small single-center cohort via leave-one-out cross-validation and has not been validated in an independent population.